Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
A new magnetic gene therapy technology allows for precise control of specific brain circuits non-invasively with magnetic fields. The technology has shown promise in reducing abnormal movements in a mouse model of Parkinson's disease, and may have potential applications for treating psychiatric disorders and chronic pain.
Researchers from Charité have shown that deep brain stimulation using electrical impulses can accelerate movement and shorten delays in Parkinson's patients. By decoding the intent preceding voluntary movement seconds before action, they discovered that dopamine significantly speeds up this process.
Researchers create Lewy bodies in living dopaminergic neurons using human stem cells and find that immune challenge is crucial for their formation. The study identifies a previously unknown link between the immune system and neurological disease, suggesting that genetic predisposition may not be necessary for Parkinson's development.
Researchers at the University of California, Irvine have identified ophthalmic acid as an alternative neurotransmitter that reverses movement deficits in Parkinson's patients. The study found that ophthalmic acid binds to calcium-sensing receptors, offering a promising new avenue for treating movement disorders.
University of Rochester researchers have refined a noninvasive method called BL-OG that harnesses light to activate neurons in the brain. The technique has the potential to transform invasive procedures used to treat Parkinson's disease and other neurological conditions by providing a safer, less invasive alternative.
Researchers at NYU Langone Health will use visible-light OCT technology to detect biomarkers of neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. The study aims to identify retinal layers and monitor the effects of therapies.
Researchers trained an automatic speech recognizer on recordings from people with dysarthria related to Parkinson's disease, achieving a 30% accuracy improvement. The study, led by Mark Hasegawa-Johnson, provides valuable data for improving voice recognition devices.
Researchers at Fujita Health University have discovered critical impairments in purine metabolism and ATP recycling in patients with Parkinson's disease. The study highlights the importance of enhancing ATP production to slow disease progression and improve quality of life.
A team of scientists has identified a new genetic mutation in the SGIP1 gene that may cause early-onset Parkinsonism. The mutation affects brain cell communication, leading to synaptic dysfunction and recessive Parkinsonism. This discovery provides new insights into the disease's development and potential treatment strategies.
Researchers identified the external globus pallidus as responsible for impaired decision-making in mice with Parkinson's disease treated with pramipexole. Hyperactivation of this region was linked to poor risk-taking behavior and reduced effectiveness of treatments.
A novel drug molecule has been found to reactivate a crucial protein called parkin, which plays a key role in maintaining healthy brain cells. The study's findings lay the foundation for the design of personalized treatments for younger patients with specific mutations, offering new hope for a cure for Parkinson's disease.
Researchers comprehensively reviewed cerebellar involvement in Parkinson's disease, highlighting the pathophysiological role of the cerebellum in motor and non-motor symptoms. Studies showed abnormal α-synuclein aggregation, neurodegeneration, and altered functional connectivity between the cerebellum and other brain regions.
A class of diabetes medications called SGLT2 inhibitors may reduce the risk of dementia and Parkinson's disease. The study found that people taking these drugs had a 20% lower risk of developing Alzheimer's disease, 30% lower risk of vascular dementia, and 20% lower risk of Parkinson's disease.
A population-based study found that air pollution may lower Parkinson disease risk by modifying the disease phenotype and reducing dyskinesia. The study suggests a potential connection between air quality and Parkinson's disease progression.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
A research team at Hiroshima University developed an analytical pipeline to identify unexploited genes associated with Parkinson's disease and oxidative stress. The study revealed two novel candidate genes, NUPR1 and UHRF2, which were absent from current gene-disease associations databases.
Researchers at UCSF develop a method to target GTPases, enzymes involved in Parkinson's and many other diseases, by using drugs targeting the K-Ras oncogene. This approach reveals new drug binding sites that could not be predicted by computational tools.
A study of 500,000 UK participants found insulin resistance associated with higher risk of 26 conditions, such as sleep disorders and pancreatitis, and lower risk of five diseases, including anaemia and Parkinson's disease. Insulin resistance also linked to increased mortality risk in women.
Researchers have developed an integrated optical sensor capable of detecting dopamine directly from unprocessed blood samples. This breakthrough enables low-cost and efficient screening tools for various neurological conditions and cancers.
A study published in The EMBO Journal reveals that PQBP3 plays a crucial role in stabilizing the nuclear membrane, which is destabilized in senescent cells and contributes to neurodegenerative disorders. PQBP3's dysfunction may lead to the degradation of Lamin B1, a protein essential for maintaining the nuclear membrane.
A new study published in Neurology found that acute kidney injury is associated with an increased risk of developing dementia. The study analyzed data from over 300,000 individuals and found a 49% higher risk of dementia overall, with significant increases for specific types of dementia such as Lewy body dementia and vascular dementia.
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
A large study of female participants found no association between migraine and the development of Parkinson's disease, contrary to previous research. The study followed over 39,000 women for an average of 22 years and adjusted for various risk factors.
A preclinical study found that enhancing PGK1 activity can restore neuronal energy supply in low-fuel conditions, preventing axon dysfunction and degeneration. The researchers also discovered the unexpected role of DJ-1 as an energy-supplying partner of PGK1.
A scoping review from the University of Gothenburg found that music-based movement therapy, known as the Ronnie Gardiner Method, can improve rehabilitation outcomes in individuals with brain disorders. The method has been shown to be challenging, motivating, and enjoyable for participants, leading to improved recovery and quality of life.
A small NIH-funded trial found an implanted device regulated by brain activity can provide continual and improved treatment for Parkinson’s disease symptoms. The study showed adaptive deep brain stimulation (aDBS) was markedly more effective at controlling PD symptoms compared to conventional DBS treatments.
Researchers at UCSF have developed intelligent brain pacemakers that use AI to monitor and adjust brain activity in real-time, providing personalized treatment for Parkinson's patients. The approach, called adaptive deep brain stimulation, has shown promise in reducing symptoms such as movement problems and insomnia.
A wearable sensor supported by machine learning models can continuously monitor and quantify FOG episodes, providing an accurate picture of a patient's condition. This technology has the potential to support the development of new treatments and improve the lives of people with Parkinson's disease.
Researchers successfully restored the brain's waste-clearing process by reviving cervical lymph vessel function in aging mice, utilizing a known drug to boost efficiency. This breakthrough could pave the way for future therapies targeting neurodegenerative diseases.
Researchers developed a technique using videos and machine learning to quantify motor symptoms in early-stage Parkinson's disease. The approach achieved high accuracy in distinguishing between healthy individuals and those with early Parkinsonism, offering potential benefits for treatment outcomes.
Scientists at deCODE genetics have discovered rare sequence variants in ITSN1 linked to Parkinson's Disease. These variants may contribute to disease pathogenesis through CDC42 dysregulation and dopaminergic neuron degeneration.
A study by researchers at São Paulo State University found that dopaminergic medication levodopa improves sleep quality in Parkinson's disease patients. The number of times patients woke up during the night fell by 25% and the amount of time they remained awake fell 30% on average.
Researchers found that artificial induction of GluCer leads to cellular senescence in DA neurons, highlighting the role of lipid aggregation in PD. The study proposes that lysosomal impairment and lipid accumulation trigger expression of a cellular senescence phenotype in vulnerable DA neurons.
Seoul National University researchers developed a biodegradable electronic tent technology that enables non-invasive brain disease diagnosis using a needle. The device unfolds to cover the entire brain over a large area and naturally decomposes in the body after diagnosis, minimizing side effects.
Researchers developed a new visual diagnostic technique called Cap-QuIC that can distinguish infected samples with the naked eye, enabling faster and more accurate disease detection. The method builds upon previous groundbreaking diagnostic techniques and leverages simple action to detect misfolded alpha-synuclein proteins.
Researchers at Osaka Metropolitan University found that Ecklonia cava polyphenols can protect against neurodegeneration and improve motor function in Parkinson's disease model mice. The antioxidants activate the AMPK enzyme and inhibit reactive oxygen species production, reducing neuronal cell death.
Researchers discovered elevated levels of neurofilament light chain protein in Parkinson's disease and dementia with Lewy bodies, suggesting potential early detection methods. The study found different protein patterns between the prodromal stage and established diseases.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
Researchers found that fecal microbiota transplantation did not offer significant improvements in motor and non-motor symptoms of Parkinson's disease. Further studies on modified approaches or bowel cleansing are needed to better understand the impact of donor microbiota composition.
Researchers at Brigham and Women's Hospital developed a 'Parkinson's in a dish' model that rapidly converts stem cells to brain cells with protein structures characteristic of the disease. The study enables the study of Parkinson's disease pathology in a petri dish, paving the way for personalized diagnostic and treatment methods.
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
Two proteins, NAP1 and SINTBAD, have been discovered as regulators of mitophagy in cells. This discovery opens a new area of focus for researchers targeting drug therapies to boost mitophagy activity and promote mitochondrial and neuronal health.
A new video-processing technique developed at the University of Florida uses artificial intelligence to track Parkinson's disease progression in patients, allowing neurologists to better monitor their condition and quality of life. The system analyzes video recordings of patients performing the finger-tapping test, a standard test for ...
Researchers found a blood test to detect alpha-synuclein protein shows promise for diagnosing Parkinson's disease. The study, published in the Journal of Parkinson's Disease, confirmed that the biomarker is highly sensitive and changes over the course of the disease.
Researchers created a new cortical surface template called 'OpenNeuro Average' that provides greater accuracy and efficiency in analyzing neuroimaging data. The template is based on the geometric shape of the brain and can be used for studies on cognition, clinical neuroscience, autism, and neurodegenerative diseases.
Researchers at Weill Cornell Medicine used machine learning to define three subtypes of Parkinson’s disease, each with distinct driver genes and molecular mechanisms. These subtypes may suggest customized treatment strategies for patients, potentially targeting specific drugs such as metformin to slow down progression.
A study of 481 deceased athletes found that most developed parkinsonism due to CTE pathology, not classic Parkinson's disease. Researchers identified a link between contact sport participation and severe brain cell death in the brainstem.
A cross-sectional study of CTE patients found that years of contact sports participation are linked to substantia nigra pathology, leading to parkinsonism. The study suggests that repetitive head impacts may trigger neuropathologic processes in individuals with CTE.
Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.
Researchers discovered a new genetic cause of inherited Parkinson's disease, the CARS E795V mutation, which affects protein function and leads to neurological symptoms. The study found that this rare mutation is responsible for the condition in nine individuals from four families.
A major clinical trial led by the University of Nottingham found that LSVT LOUD was more effective at reducing the impact of voice problems in people with Parkinson's disease compared to no speech and language therapy or NHS delivered therapy. The treatment improved communication skills, enabling participants to go out and socialize wi...
A trial published in The BMJ highlights the need to optimise speech therapy resources for people with Parkinson’s disease. LSVT LOUD is more effective than conventional NHS speech and language therapy or no therapy in improving voice handicap scores.
A study published in The Journal of Neuroscience found that blocking a protein called Activin A can halt dyskinesia symptoms and effectively erase the brain's 'bad memory' response to certain Parkinson's treatments. This could lead to longer-term use of L-DOPA for patients.
A study published in Radiology found that brain connectivity on MRI scans can predict the progression of brain atrophy in patients with mild Parkinson's disease. The researchers used MRI data to generate a map of the brain's neural connections, which showed potential in predicting gray matter atrophy accumulation over time.
A new study by UCL researchers found that people with anxiety over the age of 50 are at least twice as likely to develop Parkinson's disease. The study, published in the British Journal of General Practice, also identified symptoms such as depression, sleep disturbance, and fatigue as risk factors for developing the condition.
Researchers found that men taking terazosin-type medications had about a 40% lower risk of developing dementia with Lewy bodies compared to those taking tamsulosin or 5-alpha reductase inhibitors. The study suggests that these drugs may have broad potential for treating neurodegenerative conditions.
A team of researchers has developed a simple blood test that uses artificial intelligence (AI) to predict Parkinson's disease up to seven years before the onset of symptoms. The test analyzes a panel of eight blood-based biomarkers with concentrations altered in patients with Parkinson's, providing a diagnosis with 100% accuracy.
Dorothee Dormann and Edward Lemke propose a new concept to measure the individual risk of getting age-related diseases by analyzing protein clumps in cells. This 'protein aggregation clock' could help diagnose age-related diseases at early stages or identify people at higher risk.
Researchers found a link between gut microbiota and Parkinson's disease, revealing reduced B vitamins and intestinal barrier issues. Treatment with B vitamins could alleviate PD symptoms and slow disease progression.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.